Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin.
about
Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines.Pharmacologic resistance in colorectal cancer: a reviewThe changing face of chemotherapy in colorectal cancerA polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracilPharmacogenetic aspects in treatment of colorectal cancer--an update.Advances in combined radiation therapy for the management of rectal cancer.Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine.Pancytopenia and Severe Gastrointestinal Toxicities Associated with 5-Fluorouracil in a Patient with Thymidylate Synthase (TYMS) PolymorphismLoss of heterozygosity at thymidylate synthase locus in Barrett's metaplasia, dysplasia, and carcinoma sequences.State of Art of Cancer Pharmacogenomics in Latin American Populations.Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 yearsAnalysis of the thymidylate synthase gene structure in colorectal cancer patients and its possible relation with the 5-Fluorouracil drug responseA phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors.Adjuvant therapy for resectable rectal adenocarcinoma.Thymidylate synthase and thymidine phosphorylase mRNA expression in primary lesions using laser capture microdissection is useful for prediction of the efficacy of FOLFOX treatment in colorectal cancer patients with liver metastasis.Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy.Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes.HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy.Treatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore C™) and 5-fluorouracil.Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma.The impact of pharmacogenomics on gastrointestinal cancer therapy.Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward?Antimetabolite incorporation into DNA: structural and thermodynamic basis for anticancer activity.MicroRNA-433 negatively regulates the expression of thymidylate synthase (TYMS) responsible for 5-fluorouracil sensitivity in HeLa cells.STRAP is a strong predictive marker of adjuvant chemotherapy benefit in colorectal cancer.Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer.Single-cell transcription site activation predicts chemotherapy response in human colorectal tumors.Recent advances in the management of carcinoma of the rectumThymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer.Systems pharmacology assessment of the 5-fluorouracil pathway.Detection of the G>C SNP and rare mutations in the 28-bp repeat of TYMS using gel-based capillary electrophoresis.Pharmacogenomics: road to anticancer therapeutics nirvana?Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery.Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects.ERCC1 and TS Expression as Prognostic and Predictive Biomarkers in Metastatic Colon CancerPhase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study.Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy.Predictive diagnostics in colorectal cancer: impact of genetic polymorphisms on individual outcomes and treatment with fluoropyrimidine-based chemotherapy.Effect of leucovorin on the antitumor efficacy of the 5-FU prodrug, tegafur-uracil, in human colorectal cancer xenografts with various expression levels of thymidylate synthaseA retrospective study on TS mRNA expression and prediction of the effects of adjuvant oral 5-fluorouracil in breast cancer
P2860
Q24799458-2232A61A-DF59-4252-8E3F-0A0C642E0F85Q26769850-FB1FCAD3-A211-404F-A865-864E04194F6DQ28345461-8DCB839A-174A-4F88-94D0-18355DBD7C37Q28352447-6DCC3B80-CDDF-4DC9-A8D9-754BDE4F2C3AQ30336665-2DB0308E-2511-4D18-A0DB-2D3ACA5FA361Q30978011-A1B82F1E-836E-4440-8646-121D6AD466FBQ33395508-DE83E35F-4D9C-46A5-A4B8-8D3FF34AC935Q33436235-2942C434-52E9-4B99-B408-F79F8D33A1B0Q33449893-08FED9AC-E7B3-44D1-8E58-51E91428C1DAQ33838298-1771F09C-729D-41E9-932F-92B498C96335Q34008793-8E8E50F8-33AF-4D14-B5B8-D74389454547Q34043033-1F4E3E44-91AC-4C7F-8509-B2FC2467F778Q34099365-4D4BCCBD-7471-41C1-9A2A-4B8C6FEB9D9EQ34176699-6F1A2361-BCE3-417A-8CEA-BCE156AD37BEQ34333072-A68656C4-F8FB-4693-A110-EBC3D02219ABQ34349053-3C424271-2679-4429-880A-EECC51FE3CDCQ34612932-7CB201C0-1660-4ACD-979B-1408BC6A7DE7Q34654819-EB1A96BC-A1AB-42B4-A9EA-1C060C801DF6Q34693012-8012E2FB-555D-4E96-A035-18892C1954EDQ34743494-523EE6B7-DD53-4627-8340-5E3F48A9869FQ34837030-6AEB5BB9-109F-4AD3-8956-486DC628B4F3Q34847802-2E9A7251-3672-45E3-8340-40913987B911Q34850202-C95904B9-0D88-443E-AFA3-D4340187D5DAQ34894800-B1D351FB-5D27-4C83-B206-A6D1AB63F9DBQ34928876-528DA04F-7212-4E77-9D08-969F713400EBQ35000906-CDBE9A23-9C35-4294-A92E-7F107CA133E6Q35023116-952E8C97-8A81-4ACB-9EC2-5FB64DE07AF5Q35026254-8ABEC3A7-4059-432C-922E-9FBDDCAEB4F0Q35032865-4380B42B-A7AD-4934-8FA8-3D654C1CDFF6Q35072321-45B2DAF9-8F9A-401E-974E-3B20FA37EDE5Q35083755-560E86D9-B33B-4C64-858B-9414CEED2DC2Q35551155-9C4385B7-ED6E-46AC-8DFA-4E1A3C54A162Q35583987-347D9929-41A7-4EF3-B3A0-CAB4F1735DC6Q35584647-E6C0E661-3787-43F6-849F-FD16AE052359Q35666148-A46727DD-18BE-471D-AE69-8580C2D7D1E7Q35765841-B48235D7-1F6D-4739-B959-5765EC20A4C7Q35888438-DF55E8CB-FD69-48BF-A1B8-CD635842E9CEQ36117701-213B2F5B-B25E-418C-A1DE-497B58301F2DQ36142392-7B9453F3-18D8-4129-B777-781BECD01B74Q36142436-BB7DED96-1643-4E37-95BD-4E3C77C1FBDC
P2860
Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh-hant
name
Quantitation of intratumoral t ...... ouracil and weekly leucovorin.
@en
Quantitation of intratumoral t ...... ouracil and weekly leucovorin.
@nl
type
label
Quantitation of intratumoral t ...... ouracil and weekly leucovorin.
@en
Quantitation of intratumoral t ...... ouracil and weekly leucovorin.
@nl
prefLabel
Quantitation of intratumoral t ...... ouracil and weekly leucovorin.
@en
Quantitation of intratumoral t ...... ouracil and weekly leucovorin.
@nl
P2093
P1476
Quantitation of intratumoral t ...... ouracil and weekly leucovorin.
@en
P2093
C G Leichman
K Danenberg
L Leichman
P V Danenberg
P304
P356
10.1200/JCO.1997.15.10.3223
P407
P577
1997-10-01T00:00:00Z